Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial.
Mamoru ShibataAtsuko NihiraYuka TanjiAkichika OzekiHideyuki ImagawaMika KomoriPublished in: Neurology and therapy (2023)
ClinicalTrials.gov identifier, NCT02959177.
Keyphrases